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Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, represents a major burden to patients
and health care systems through its sequelae of heart failure and stroke. Its age-dependent increase in preva-
lence has led to worrisome predictions of an expanding burden secondary to our aging population. This growing
epidemic is further exacerbated by a current lack of highly effective therapies for the arrhythmia stemming from
our incomplete understanding of its complex pathophysiology. Recent genetic studies, triggered in part by evi-
dence of a hereditary component of AF, have begun to identify predisposing genes and offer further insights into
the mechanisms of lone AF. A variety of ion channels and most recently a circulating hormone have been impli-
cated. The apparent genetic diversity underlying the arrhythmia has served to emphasize the heterogeneity of
factors that govern its initiation and maintenance. The different causative genes seem to predispose to AF
through distinct putative mechanisms, including enhanced and delayed atrial action potential repolarization, cel-
lular hyperexcitability, and conduction velocity heterogeneity. Classification of lone AF into mechanistic sub-
groups serves to emphasize its heterogeneity and has the potential to guide developmental and clinical treat-
ment strategies. The frequent recalcitrant nature of the arrhythmia to contemporary pharmacological and
invasive therapies may be overcome through an ability to identify, through genetics, the mechanistic subclass of
AF for an individual patient. Proper identification of the culprit pathophysiology may permit administration of a
targeted form of therapy that carries maximal efficacy and minimal risk in a manner consistent with the vision
of pharmacogenomics. (J Am Coll Cardiol 2010;55:705–12) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.005o
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mtrial fibrillation (AF), the most common sustained cardiac
rrhythmia, represents a major health burden to individuals
nd health care systems within the Western world (1). The
ifetime risk of the development of AF at age 40 years has
een estimated to be approximately 1 in 4 (2). Through its
equelae of stroke and heart failure, along with serving as an
ndependent risk factor for death, AF is currently estimated
o cost the American health care system more than $1
illion annually (1,3). Given its increasing prevalence with
ge, coupled with our aging population, the number of
ffected Americans is expected to surge from approximately
.3 million in the year 2000 to nearly 16 million by 2050 (4).
hese worrisome prospects are further exacerbated by our
urrent lack of highly effective therapies.
Rational design of effective therapies requires improved
nsight into the factors that govern both the initiation and
aintenance of the arrhythmia. Indeed, more than one-half
century after the initial proposal of the multiple wavelet
ypothesis by Gordon Moe, there continues to be a variety
rom the Arrhythmia Research Laboratory, University of Ottawa Heart Institute,
ttawa, Ontario, Canada.o
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009, accepted December 8, 2009.f proposed theories regarding the precise electrical phe-
omena that define the arrhythmia (5,6). This lack of
onsensus likely reflects, as opposed to incorrect competing
heories, heterogeneity in the pathophysiologic processes
hat trigger and perpetuate AF.
Insight into the diverse mechanisms governing lone AF
as been furthered by the discovery of specific genes that
redispose to the arrhythmia. Evidence of a genetic contri-
ution in the development of AF was first provided in 1943
y Wolff (7), who documented transmission of lone AF in
family with an autosomal dominant pattern of inheritance.
ince that time, large epidemiologic studies have docu-
ented evidence of heritability in AF, in particular in the
ontext of lone AF (8–10). In 2003, the first gene respon-
ible for an autosomal dominant form of familial AF was
dentified, namely, KCNQ1 (11). Encoding a potassium
hannel, this work was followed by subsequent studies that
mplicated numerous other genes encoding ion channels in
he pathogenesis of AF. As an exception, the most recent
ulprit gene identified encodes a circulating hormone, the
trial natriuretic peptide (ANP) (12). These diverse proteins
re thought to predispose to AF through different electrical
echanisms, a notion that emphasizes the degree of heter-
geneity that governs initiation and maintenance of the
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underlie the variable efficacy of non-
specific, contemporary treatment
strategies for AF, thereby rein-
forcing the need for improved
insight into the subtypes of lone
AF to facilitate targeted therapy
that carries maximal efficacy and
minimal risk.
Classification of lone AF into
subtypes on the basis of causative
mechanisms and their putative
effects on atrial electrophysiology
serves to highlight the heteroge-
eous physiology that contributes to the disorder. Such a
lassification approach may ultimately serve as a guide for
linical treatment strategies consistent with a pharmacog-
nomic paradigm (Table 1).
echanisms of Lone AF
nhanced atrial action potential repolarization. The first
ausative gene for AF, KCNQ1, was identified through a
inkage analysis study of a Chinese family with an autosomal
ominant form of lone AF (11). KCNQ1 encodes the pore
orming -subunit of the Kv7.1 voltage-gated potassium
hannel that is responsible for the slow component of the
elayed rectifier potassium current (13). As illustrated in
igure 1A, the slow component of the delayed rectifier
otassium current contributes to repolarization of cardiac
yocytes (13). The importance of KCNQ1 in cardiac
rrhythmogenesis was previously documented through its
dentification as the causative gene for congenital long QT
yndrome (LQTS) type 1 (14). Family members with AF
ere found to carry a mutation affecting amino acid position
40 that resulted in the substitution of a glycine for a serine
esidue (Ser140Gly) (11). In vitro functional analysis re-
ealed markedly increased current densities conducted by
he mutant channel indicating that, unlike the KCNQ1
oss-of-function mutations observed in LQTS type 1, the
Abbreviations
and Acronyms
AF  atrial fibrillation
ANP  atrial natriuretic
peptide
APD  action potential
duration
Cx40  connexin 40
ERP  effective refractory
period
LQTS  congenital long
QT syndrome
Mechanistic Subclassification of Lone AFTable 1 Mechanistic Subclassification of Lo
AF Subclassification Culprit Ge
1. Enhanced atrial action potential
repolarization
KCNQ1 (11
KCNE2 (17
KCNJ2 (18)
KCNE5 (19
2. Delayed atrial action potential
repolarization
KCNA5 (28
SCN5A (35
3. Conduction velocity heterogeneity GJA5 (40)
4. Cellular hyperexcitability SCN5A (44
5. Hormonal modulation of atrial
electrophysiology
NPPA (12)
6. Cholinergic Unknowner140Gly substitution resulted in a gain of function (11).
nterestingly, QT prolongation on electrocardiography was
vident in 9 of 16 affected patients, suggesting that the
utation may have opposing electrophysiological effects in
trial and ventricular tissue. Subsequently, other KCNQ1
ain-of-function mutations have been reported to be asso-
iated with familial and sporadic cases of AF (15,16). After
he identification of KCNQ1 as a causative gene for AF,
ultiple other gain-of-function mutations within potassium
hannel genes have been reported in association with AF
nd normal QT intervals, including KCNE2, KCNJ2, and
CNE5 (17–19). Further evidence supporting the role of
otassium channels in AF comes from the observation that
s many as 30% of patients with short QT syndrome, a
ondition that develops secondary to KCNQ1 or KCNH2
ain-of-function mutations, have frequent paroxysms of AF
20,21).
The predicted physiological consequences of gain-of-
unction mutations within potassium channels include an
cceleration of cardiomyocyte repolarization. This enhanced
epolarization results in a shortening of the overall action
otential duration (APD) and presumably a related reduc-
ion in the effective refractory period (ERP) (Fig. 1C). This
educed ERP is likely responsible for the increased predis-
osition for AF in these affected families, a concept that is
onsistent with the multiple wavelet hypothesis.
The multiple wavelet hypothesis, which suggests that the
rregular atrial activity associated with AF is secondary to
ultiple self-perpetuating micro–re-entrant circuits exhib-
ting spatiotemporal variability in conduction and refracto-
iness, was proposed by Moe et al. (5,22) in 1959 following
xperimental work with dogs and was supported by a
ubsequent mathematical model. The theory, which became
he dominant conceptual model of AF, received further
alidation approximately 3 decades later when high-
esolution electrode mapping systems recorded multiple
andomly propagating wavelets as the cause of turbulent
trial activity in human hearts (23). Central to this self-
ustaining model is the requirement for a critical number of
F
Functional Effect
) Enhanced slow component of the delayed
rectifier potassium current (IKs)
Enhanced KCNQ1-KCNE2 potassium current
Enhanced inward rectifier current (IK1)
Enhanced IKs
Decreased ultrarapid component of the delayed
rectifier potassium current (IKur)
Hyperpolarizing shift in Nav1.5 inactivation
Decreased gap junction conduction
Depolarizing shift in Nav1.5 inactivation
Increased circulating levels of mutant atrial
natriuretic peptide
Enhanced cholinergic sensitivityne A
ne(s)
,15,16
)
)
)
)
,45)
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February 23, 2010:705–12 Genetic Classification of Lone AFirculating wavelets to maintain sufficiently chaotic activity
o prevent coalescence of colliding wave fronts within the
tria (22). The initial mathematical model by Moe and
bildskov (22) suggested that a minimum of 15 to 30
avelets were necessary to sustain the arrhythmia, although
ubsequent work has indicated that as few as 4 to 6 wavelets
ay be sufficient in the canine heart (5,24). The number of
avelets that can be established and sustain AF is depen-
Figure 1 Effect of Ion Channels on Atrial APD
(A) Atrial action potential. (B) Loss-of-function sodium channel gene mutation resu
action potential duration (APD). (C) The delayed rectifier potassium currents. A ga
rent and a shortening of atrial APD. A loss-of-function potassium channel gene muent on both atrial size and a concept termed the wave- sength of re-entry. The wavelength of re-entry concept may
e viewed as a means to predict the size of a micro–re-
ntrant circuit using the product of conduction velocity and
RP (25). A reduction in ERP results in the formation of
maller micro–re-entrant circuits, allowing an increased
umber of circulating wavelets within atria of a given size.
he aforementioned gain-of-function mutations, through
nhanced repolarization and reduced ERP, therefore pre-
n a hyperpolarizing shift in steady-state inactivation and a prolongation of atrial
nction potassium channel gene mutation causes an increased repolarizing cur-
results in a decreased repolarizing current and prolongation of atrial APD.lting i
in-of-fu
tationumably increase the potential number of circulating atrial
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Genetic Classification of Lone AF February 23, 2010:705–12avelets and promote perpetuation of AF through a mech-
nism consistent with the multiple wavelet hypothesis.
elayed atrial action potential repolarization. The dis-
overy that gain-of-function mutations within potassium
hannels predispose to lone AF was consistent with the
ominant conceptual model of AF. However, evidence of
echanistic heterogeneity was suggested by contemporary
lectrophysiology studies involving both animals and hu-
ans. Administration of cesium chloride, a potassium
hannel blocker, into the sinus node artery of dogs induced
arly afterdepolarizations that triggered polymorphic atrial
achycardias with subsequent degeneration into AF (26).
his finding prompted the investigators to coin the term
trial torsade de pointes (26). Support for this concept in
umans was provided by electrophysiology studies on pa-
ients with LQTS that revealed prolongation of both atrial
PDs and ERPs along with short, spontaneous episodes of
olymorphic atrial tachycardia, a finding not observed in
ontrols (27).
Genetic support for a subtype of AF resembling atrial
orsades was obtained after identification of a loss-of-
unction mutation in the KCNA5 gene in a family with
ereditary lone AF (28). The KCNA5 gene encodes the
v1.5 voltage-gated potassium channel responsible for the
ltrarapid component of the delayed rectifier potassium
urrent (28). The identified E375X mutation resulted in the
rroneous insertion of a stop codon at position 375, which
ed to the expression of a truncated protein that was unable
o conduct any significant current during in vitro functional
nalysis (28). Unlike the previous gain-of-function muta-
ions, a loss-of-function mutation of the Kv1.5 voltage-
ated potassium channel would result in delayed action
otential repolarization and an increased ERP (Fig. 1C).
ubsequent in vitro and in vivo studies inducing a reduction
n Kv1.5 current through the use of 4-aminopyridine, a
pecific Kv1.5 blocker, revealed early afterdepolarizatons
riggering episodes of AF, providing support for the concept
f atrial torsades (28).
Another ion channel with a known role in mediating
PD is the voltage-gated sodium channel Nav1.5 (13).
ncoded by the SCN5A gene, Nav1.5 is already associated
ith numerous other disorders that carry an increased risk of
F, including Brugada syndrome, LQTS type 3, and sick
inus syndrome (29–31). In the 2 largest reported cohorts of
rugada syndrome patients assessed for coexisting AF, the
revalence of AF was in the range of 15% (32,33). Muta-
ions of SCN5A were reported in 20% of patients with AF,
lthough the biophysical properties of these variants were
ot assessed. A study involving 375 lone AF patients
dentified 8 novel mutations in 10 separate probands, 6 of
hom had a family history of the arrhythmia (34). Al-
hough biophysical functional work was not performed,
dentified mutations seemed to segregate with the disease,
roviding evidence of causality. Subsequently, physiological
onsequences of a loss-of-function SCN5A mutation in lone
F have been described. In a small kindred harboring a aovel Asn1986Lys mutation, the variant was characterized
y a loss of function, demonstrating a hyperpolarizing shift
n steady-state inactivation, which would be predicted to
rolong APD (Fig. 1B) (35). Although not investigated
urther, this mutation would presumably predispose to AF
hrough a manner consistent with the previously described
trial torsades.
A form of AF initiated by delayed atrial repolarization,
ith an ensuing pathophysiology reflective of atrial torsades,
ontrasts markedly with AF that behaves in accordance with
he multiple wavelet hypothesis promoted by reduced ERP.
his mechanistic heterogeneity may provide insight into the
ariable response observed in different individuals treated
ith identical forms of therapy, such as potassium or
odium channel–blocking agents.
onduction velocity heterogeneity. Although the initial
enes implicated in familial AF encoded potassium chan-
els, subsequent screening of lone AF cohorts suggested
hat these channels were a rare cause of the arrhythmia
36,37). These findings implied that there were likely other
lasses of genes that played an important role in the develop-
ent of the more common sporadic form of AF. Attractive
andidate genes included connexins, transmembrane-
panning proteins that form gap junctions, which serve as
ntercellular pores, providing low-resistance pathways for
he passage of current between adjacent cells (38). Of the 5
onnexin isoforms expressed in the heart, connexin 40
Cx40) seemed the most intriguing in the context of AF
iven its high level of expression within the atria and
bsence from ventricular myocardium (39).
Work by our group involving cases of sporadic lone AF
dentified Cx40 mutations in 4 of the 15 patients screened
40). In vitro characterization revealed a loss of function of
he Cx40 mutant proteins secondary to intracellular traf-
cking defects and/or impaired cell-to-cell coupling.
qually important, the Cx40 mutations seemed to be of
omatic rather than germ cell origin in 3 of the 4 cases. In
hese 3 cases, the mutant form of Cx40 was identified only
rom atrial tissue and was absent from the peripheral
ymphocytes of affected patients. Through allele subcloning
nalysis from atrial tissue, the proportion of atrial cells
stimated to harbor the mutant connexins ranged from 20%
o 34% (40). This inhomogeneous distribution of loss-of-
unction gap junctions would be expected to promote or
xaggerate regional differences in conduction velocity, cre-
ting a heterogeneous substrate promoting electrical re-
ntry. Immunostaining of atrial tissue specimens from
ffected patients carrying the trafficking-defective Cx40-
ro88Ser mutant revealed a mosaic multicellular pattern of
ntracellular retention, supporting the heterogeneous nature
f somatic or tissue-specific mutations within a subpopula-
ion of atrial myocytes.
The loss of function associated with these connexin
utations, coupled with their heterogeneous distribution
hroughout the atria, likely results in a predisposition to AF
nd maintenance of the arrhythmia through mechanisms
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February 23, 2010:705–12 Genetic Classification of Lone AFonsistent with an enhanced vulnerability to electrical re-
ntry in the context of an exaggerated dispersion of con-
uction velocity (Fig. 2). This gap junction-induced spatio-
emporal variability of conduction and tissue refractoriness
llows for the establishment of the multiple re-entrant
ircuits necessary to satisfy the multiple wavelet hypothesis
nd therefore create a sustained form of AF.
ellular hyperexcitability. The concept of cellular hyper-
xcitability received much attention after a landmark article
hat documented rapidly firing ectopic foci from the pul-
onary veins that were sufficient to both trigger and
aintain AF (41). Studies involving isolated sheep heart
emonstrated that a rapid self-sustaining circuit of re-entry,
ermed a mother rotor, is capable of transmitting fraction-
ted spiral waves to adjacent atrial tissue at a frequency
ufficient to both induce and maintain AF (42). Figure 3
llustrates a rapidly firing ectopic focus in the vicinity of a
ulmonary vein os mediating AF through disorganized
ropagation of wave fronts to surrounding tissue. Support
or a rapid self-sustaining re-entry circuit as the mechanism
riving the ectopic foci in AF has subsequently come from
igh-resolution optical mapping of canine pulmonary vein
leeves (43). The factors contributing to these foci are not
ntirely clear; however, they may include aberrant vagal
nfluences from nearby autonomic ganglia coupled with the
omplex architecture of the pulmonary veins or posterior left
trium that result in an ideal substrate for re-entry.
Figure 2 Micro Circuit Re-Entry Secondary to Conduction Veloc
(A) Atrial fibrillation depicted on electrocardiography and conceptually within the he
encounters refractory tissue and terminates, whereas wave front B travels along a
previously refractory tissue to repolarize. Wave front B now encounters excitable ti
current through gap junctions resulting in normal conduction velocity. (D) DecreaseEstablishment of a high-frequency micro–re-entrant cir-
uit within the pulmonary veins requires a trigger for
nitiation, and therefore ion channels involved in depolar-
zation are likely critical to this pathophysiologic process.
n obvious candidate includes the previously discussed
av1.5 responsible for the predominant inward sodium
urrent during early cellular excitability. At this point, there
ave been 2 studies that identified SCN5A gain-of-function
utations in patients with lone AF who did not have LQTS
ype 3, the only previous condition associated with SCN5A
ain-of-function mutations (30). In 1 study, affected mem-
ers of a Japanese family with an autosomal dominant form
f lone AF harbored a novel M1875T mutation (44).
unctional analysis of the mutant channel using in vitro
tudies revealed a pronounced depolarizing shift in the
oltage-dependent steady-state inactivation of the channel,
hich is predicted to lower the threshold potential for
ellular excitability. This concept of cellular hyperexcitabil-
ty was supported by observations from radiofrequency
atheter ablation of the proband in which numerous ectopic
rings and increased excitability of the right atrium were
ocumented (44). Another study from our group identified
K1493R mutation in a mother and son who had lone AF
hat exhibited a similar depolarizing shift in steady-state
nactivation when expressed in tsA201 cells (45). In addi-
ion, transfection of the mutant K1493R into HL-1 atrial
ardiomyocytes resulted in spontaneous action potential
eterogeneity
) An ectopic impulse triggering depolarizing wave fronts A and B. Wave front A
nate pathway of slowed conduction velocity providing a time delay allowing the
and a re-entry circuit is established. (C) Cell-to-cell transmission of depolarizing
duction velocity secondary to loss-of-function gap junction channels.ity H
art. (B
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Genetic Classification of Lone AF February 23, 2010:705–12epolarizations and a lower threshold for action potential
ring. Of note, the late persistent current characteristic of
ain-of-function SCN5A mutations responsible for LQTS
ype 3 was absent in the mutants from both studies, thus
ccounting for the normal QT interval in these patients.
The mechanism translating cellular hyperexcitability sec-
ndary to SCN5A gain-of-function mutations into the
henotype of AF potentially relates to enhanced automa-
icity of atrial cardiomyocytes. The resultant triggers, in the
etting of an ideal substrate such as the pulmonary veins,
ay be sufficient to both induce and maintain AF. A
omplementary mechanism may involve the intracardiac
anglia that densely innervate this region of the heart (46).
ecent work revealed that Nav1.5 channels are highly
xpressed within intracardiac ganglia, alluding to the pos-
ibility that hyperexcitability of surrounding neurons may be
he driving force behind the rapidly firing ectopic foci (47).
The distinct electrophysiological features of an AF
riven by cellular hyperexcitability again serve to rein-
orce the clinical relevance of a subclassification system
or lone AF. Treatment strategies effective against a form
f AF reflective of the multiple wavelet hypothesis, such
s potassium channel blockers, would likely be ineffective
n the case of focal forms of AF driven by cellular
yperexcitability. Sodium channel modification affecting
he kinetics of Nav1.5 channel inactivation might provide
more efficacious response in the setting of cellular
yperexcitability.
ormonal modulation of atrial electrophysiology. NPPA
Figure 3 Atrial Fibrillation Secondary
to Cellular Hyperexcitability
A rapidly firing ectopic focus in the vicinity of a pulmonary vein os transmitting
electrical wave fronts to adjacent atrial tissue with sufficient spatiotemporal
dispersion to generate atrial fibrillation.epresents the most recent gene identified as being causative oor AF and, unlike the previously implicated genes that
nvolve ion channels, encodes the circulating hormone ANP
12). This somewhat surprising discovery was obtained from
linkage analysis study of a family with an autosomal
ominant form of lone AF (12). Before this work, ANP had
enerally been viewed as a cardioprotective hormone with
n important role in sodium balance and blood pressure
egulation (48). There was evidence, however, that ANP
as capable of modulating the activity of various ion
hannels within the heart (49,50).
The mutation identified in the affected family resulted in
he loss of the stop codon, resulting in the expression of a
0-amino-acid peptide that was significantly longer than
he 28-amino-acid wild-type peptide (12). The mutant
eptide was detected in the plasma of heterozygote carriers
nd was present at 5- to 10-fold the concentration of
ild-type ANP, suggesting resistance to degradation and a
rolonged half-life. The mechanism through which this
utant peptide triggered AF was not entirely clear; how-
ver, in vitro studies using an isolated whole heart model
uggested that the mutant peptide shortened the atrial APD
ith a corresponding effect on the ERP (12). These findings
llude to a mechanism involving enhanced repolarization
nalogous to that observed with gain-of-function potassium
hannel mutations.
Although the potential role of ANP in directly modulat-
ng atrial electrophysiology and promoting an AF substrate
s intriguing, other proarrhythmic actions of ANP are also
onceivable, an example being inflammation that could stem
rom the important role of ANP in the regulation of the
nnate immune system (51,52). Given that ANP is a known
ediator of inflammation, long-term exposure to altered levels
f ANP might induce structural changes related to inflamma-
ion that ultimately result in atrial fibrosis and subsequent
evelopment of an AF substrate. Further work will be required
o further our understanding into the mechanisms through
hich mutant ANP predisposes to AF.
holinergic AF. Genes encoding multiple different ion
hannels and now a circulating hormone have been impli-
ated as predisposing factors to AF. However, somewhat
urprisingly, there is as yet no described genetic link within
critical pathway in the arrhythmogenesis of AF, the
utonomic nervous system. Sympathetic and parasympa-
hetic influences have long been appreciated as mediators of
he triggers and substrate modification necessary for the
evelopment of AF. The notion of a vagally mediated form
f AF was first suggested by Coumel et al. (53) more than
decades ago in a report that described a cohort of young
atients with structurally normal hearts in whom recurrent
aroxysms of AF developed during periods of high vagal
one such as sleep and the postprandial period. Although
ympathetic influences seem to be the predominant medi-
tor of AF in diseased hearts, vagal input serves as the major
ulprit in the setting of lone AF.
The greatest density of vagal innervation within the atriaccurs at the pulmonary veins, which correspond to the
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February 23, 2010:705–12 Genetic Classification of Lone AFocation of rapidly firing ectopic foci capable of driving the
rrhythmia (41,46). Identification of the pulmonary veins as
frequent source of rapidly firing ectopic foci provided the
ationale for contemporary AF treatment strategies that use
atheter ablation techniques to electrically isolate the pul-
onary veins from surrounding atrial tissue (54). Although
he complex architecture of the pulmonary veins likely
erves as an ideal substrate for re-entry, the role of auto-
omic ganglia in the genesis of AF is becoming increasingly
pparent. Ablation procedures whereby vagal responses are
licited by radiofrequency ablation in the regions of the
ulmonary veins have shown increased efficacy, suggesting
hat the lesions are affecting vagal input or ganglia (55).
his is complemented by recent studies in a dog model of
holinergic AF that demonstrated that electrical isolation of
ulmonary veins alone could not suppress vagally stimulated
F, whereas ablation of the autonomic ganglia overlying all
ulmonary vein ostia succeeded in suppressing AF with
agal stimulation (56). These findings identify the parasym-
athetic nervous system as a critical predisposing factor for
F, providing a clue that genetic mutations in the molecular
onstituents mediating the cardiac vagal response may
epresent an important, and potentially common, cause of
he arrhythmia.
ummary
enetic studies have revealed diverse mechanisms of AF
ulnerability secondary to genetic defects in multiple ion
hannels and a circulating hormone. This heterogeneous
athophysiology highlights the difficulties of a common
herapeutic approach to ameliorate this prevalent arrhyth-
ia. A classification system that recognizes the mechanistic
ubtypes of lone AF, as predicted by culprit genes or clinical
ata, has the potential to guide clinical treatment strategies.
s genetics are gradually incorporated into routine clinical
ractice, a classification system may facilitate individualized
F therapy based on pharmacogenomic principles.
Although single-gene disorders for AF provide the op-
ortunity to understand primary electrophysiological mech-
nisms predisposing the atria to fibrillation, it is likely that,
n many cases, disease vulnerability arises from the influence
f multiple genes that may influence the putative mecha-
isms described here. Identifying common variations within
he genome, which, either alone or in combination, may
ffect the biophysical properties of atrial tissue, remains a
riority in future research. Genome-wide association studies
ave provided insight into common genetic loci that carry
n increased risk of AF; however, the specific genes have yet
o be identified (57–59). The discovery of these genes and
nsight into their effect on atrial electrophysiology will
ndoubtedly facilitate the implementation of a pharmaco-
enomic treatment approach for this common arrhythmia.
The classification of AF as either secondary to structural
isease or as lone AF is now obsolete. It is now clear that
one AF, based on the mechanistic insights provided by
2enetic studies, requires a classification system reflecting the
pecific electrophysiological substrates that promote vulner-
bility to this heterogeneous disorder.
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